Post Transplant Cytomegalovirus Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for post transplant cytomegalovirus infection. 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
7
Active US patents
59/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Post Transplant Cytomegalovirus Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Takeda 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating post transplant cytomegalovirus infection. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
31
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Livtencity
MARIBAVIR
 Takeda 7 59 $300M 2031-10-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12447169 Livtencity method of use 81 2031-10-27
11684632 Livtencity method of use 76 2032-01-04
12213989 Livtencity method of use 75 2042-11-18
12447170 Livtencity method of use 75 2042-11-18
12433907 Livtencity method of use 75 2042-11-18
12295940 Livtencity composition of matter 17 2043-10-11
12527771 Livtencity composition of matter 17 2043-10-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12527771 Livtencity composition of matter 17 2043-10-11
12295940 Livtencity composition of matter 17 2043-10-11
12213989 Livtencity method of use 75 2042-11-18
12447170 Livtencity method of use 75 2042-11-18
12433907 Livtencity method of use 75 2042-11-18
11684632 Livtencity method of use 76 2032-01-04
12447169 Livtencity method of use 81 2031-10-27

Related